Aimmune Therapeutics Inc. (NASDAQ:AIMT) shares rose 3.8% during mid-day trading on Monday . The stock traded as high as $12.74 and last traded at $12.44, with a volume of 53,592 shares trading hands. The stock had previously closed at $11.99.

AIMT has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday, May 20th. Bank of America Corp. reissued a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Wedbush reissued an “outperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $38.00 target price on shares of Aimmune Therapeutics in a research note on Wednesday, June 29th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Aimmune Therapeutics has an average rating of “Buy” and an average target price of $33.40.

The company’s 50 day moving average is $11.54 and its 200-day moving average is $13.91. The firm’s market capitalization is $519.22 million.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Monday, May 16th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.03. On average, equities research analysts predict that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of Aimmune Therapeutics stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total transaction of $3,655,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A hedge fund recently raised its stake in Aimmune Therapeutics stock. Aisling Capital LLC boosted its stake in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,990,000 shares of the company’s stock after buying an additional 170,000 shares during the period. Aimmune Therapeutics accounts for approximately 9.5% of Aisling Capital LLC’s portfolio, making the stock its 4th largest position. Aisling Capital LLC owned 7.08% of Aimmune Therapeutics worth $55,166,000 at the end of the most recent quarter.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.